PRAMOMOLECULAR develops self-delivering siRNAs. Our therapeutic oligonucleotides can downregulate mRNAs in lung, pancreas, heart and colon. We are thus developing drug candidates to causally cure serious cancers such as lung, colon or pancreatic carcinoma or metabolic diseases, e.g. of the heart - as in Noonan syndrome. Currently, we are working on our preclinical in vivo proof of concept experiments.
A special feature of our technology is that we couple defined lipid residues directly to siRNAs via defined chemical bonds. This gives us one of the simplest, patent-protected platform technologies for introducing therapeutic oligonucleotides into organs besides the liver in vivo. This is of great therapeutic importance, as delivery of siRNAs has previously only worked in local applications, such as in the eye or muscle, or systemically in the liver. We are also providing siRNA based drug candidates for selected other organs.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2021
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was PRAMOMOLECULAR founded?
PRAMOMOLECULAR was founded in 2021.
What industry is PRAMOMOLECULAR in?
PRAMOMOLECULAR operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is PRAMOMOLECULAR based?
PRAMOMOLECULAR is headquartered in Gera, Germany.
Find investors for your startup like PRAMOMOLECULAR
Gritt sends AI-personalised outreach to each investor — from your Gmail
